Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Profit After Tax (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Profit After Tax data on record, last reported at -$19.8 million in Q4 2025.

  • For Q4 2025, Profit After Tax rose 79.5% year-over-year to -$19.8 million; the TTM value through Dec 2025 reached -$64.9 million, up 50.84%, while the annual FY2025 figure was -$64.9 million, 50.84% up from the prior year.
  • Profit After Tax reached -$19.8 million in Q4 2025 per ACRS's latest filing, down from -$14.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$1.5 million in Q4 2023 and bottomed at -$96.6 million in Q4 2024.
  • Average Profit After Tax over 5 years is -$23.2 million, with a median of -$19.9 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: surged 94.6% in 2023, then plummeted 6375.65% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$22.8 million in 2021, then fell by 21.18% to -$27.6 million in 2022, then soared by 94.6% to -$1.5 million in 2023, then tumbled by 6375.65% to -$96.6 million in 2024, then surged by 79.5% to -$19.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$19.8 million in Q4 2025, -$14.6 million in Q3 2025, and -$15.4 million in Q2 2025.